Last reviewed: September 11, 2026
Eli Lilly and Company (NYSE: LLY) is no longer merely a diversified pharmaceutical manufacturer with a promising diabetes medicine. Mounjaro and Zepbound have become a global growth engine, Lilly is investing tens of billions of dollars in manufacturing, and its cardiometabolic pipeline could broaden the franchise from injections into oral therapy and additional indications.
The business performance is exceptional. Second-quarter 2026 revenue increased 48% year over year to $23.0 billion, driven mainly by Mounjaro and Zepbound volume. But the investment question is more demanding: how much of that success is already reflected in a roughly $1 trillion market value? A great company can still be a disappointing investment if the price assumes near-perfect execution.
Eli Lilly at a glance
| Metric | Result | Investor takeaway |
|---|---|---|
| 2025 revenue | $65.18 billion | Up 45% year over year |
| 2025 GAAP net income | $20.64 billion | Nearly doubled from 2024 |
| 2Q 2026 revenue | $22.97 billion | Up 48%, with 60% volume growth partly offset by lower prices |
| 2Q 2026 GAAP operating income | $8.98 billion | Strong operating leverage despite heavy investment |
| 2Q 2026 GAAP gross margin | 85.8% | High-value product mix and improving production economics |
| 2026 revenue guidance | $85–$87 billion | Raised after the second quarter |
| 1H 2026 operating cash flow | $16.02 billion | Up from $4.75 billion in 1H 2025 |
| 1H 2026 capital expenditures | $5.26 billion | Manufacturing build-out consumes significant cash |
Sources: Lilly’s 2025 Form 10-K, second-quarter 2026 earnings materials, and second-quarter 2026 Form 10-Q. Non-GAAP measures should be read with the company’s reconciliations.
Mounjaro and Zepbound are reshaping the company
Tirzepatide is sold as Mounjaro for type 2 diabetes and Zepbound for chronic weight management and certain related indications. In 2025, Mounjaro revenue increased 99% to $22.97 billion, while Zepbound revenue rose 175% to $13.54 billion. Together they generated $36.51 billion, or 56% of Lilly’s total revenue. That concentration is both the company’s greatest strength and its largest single risk.
The momentum accelerated in 2Q 2026. Worldwide Mounjaro revenue climbed 91% to $9.9 billion. U.S. Zepbound revenue increased 44% to $4.9 billion. Mounjaro’s international revenue rose 172% to $5.2 billion as access broadened. Across the company, volume grew 60%, more than offsetting a 13% decline in realized prices. This distinction matters: adoption remains powerful, but pricing and rebates will determine how much revenue growth becomes profit.
Demand can expand through geographic launches, better reimbursement, supply improvements, and additional clinical uses. At the same time, governments and private payers have strong incentives to negotiate lower prices as treatment populations grow. Investors should track prescription volume, realized price, payer coverage, persistence on therapy, international mix, and Lilly’s ability to supply every market it enters.
Pipeline: building beyond today’s injections
Lilly’s next growth layer is designed to expand the market rather than simply replace tirzepatide. Foundayo (orforglipron), an oral GLP-1 medicine, received U.S. approval for obesity in 2026 and was submitted for type 2 diabetes. A once-daily pill without food or water restrictions could reach people who avoid injections and may be easier to manufacture and distribute at scale.
Retatrutide, an investigational triple hormone receptor agonist, reported positive results in three additional Phase 3 obesity trials. Lilly stated that the clinical package was complete to support planned global registrations for obesity, obstructive sleep apnea, and knee osteoarthritis pain, with a U.S. submission planned for the first quarter of 2027. Clinical success does not guarantee approval, label breadth, reimbursement, or commercial adoption, but retatrutide could extend Lilly’s leadership if its benefit-risk profile remains compelling.
Diversification also matters. Verzenio generated $5.72 billion in 2025, and Lilly is developing or commercializing medicines across oncology, immunology, and neuroscience, including Jaypirca, Ebglyss, Omvoh, Kisunla, and Inluriyo. Second-quarter 2026 revenue from the company’s key products in immunology, oncology, and neuroscience increased 121%. Acquisitions of Orna, Ajax, Centessa, and Kelonia added platforms and programs, though the related acquired in-process R&D charges make quarterly GAAP earnings less smooth.
Manufacturing investment is both moat and risk
Drug demand is valuable only if Lilly can produce approved medicine at consistent quality. The company is expanding manufacturing in Indiana, North Carolina, Wisconsin, Virginia, Texas, Alabama, Pennsylvania, Ireland, Germany, and the Netherlands. In May 2026, Lilly committed another $4.5 billion to two Indiana sites, bringing its Indiana capital-expansion commitments since 2020 to more than $21 billion. The facilities are intended to support products including Foundayo and, if approved, retatrutide.
This capacity can form a competitive advantage. Complex active ingredients, sterile filling, injection devices, quality systems, and regulatory qualification cannot be replicated overnight. Greater scale may also reduce unit costs, as reflected in recent margin improvement. Yet factories involve long construction and validation timelines. Delays can restrict sales; quality problems can interrupt supply; and overestimating demand can leave expensive assets underused. Manufacturing should therefore be analyzed as strategic reinvestment, not automatically treated as maintenance spending.
Margins and operating leverage
For 2025, revenue increased 45% to $65.18 billion and GAAP gross margin reached $54.13 billion, or 83.0% of revenue, up from 81.3% in 2024. GAAP net income rose 95% to $20.64 billion. The figures demonstrate substantial operating leverage, even as Lilly increased research, launch spending, and manufacturing investment.
In 2Q 2026, GAAP gross margin was 85.8%, operating income was $8.98 billion, and net income was $7.10 billion. Non-GAAP gross margin was 86.3% and non-GAAP performance margin was 54.8%. Revenue grew faster than core operating costs, but reported results also included a $2.8 billion pre-tax acquired IPR&D charge. R&D and business development are essential to the long-term model; investors should not pretend they are free simply because adjusted reporting isolates some charges.
Lilly raised 2026 revenue guidance to $85–$87 billion and non-GAAP performance-margin guidance to 49.0%–50.5%. It guided to non-GAAP EPS of $35.50–$36.50, including the effect of acquired IPR&D described in its earnings release. Guidance is not a guarantee, and first-half results benefited from sales-based milestones and adjustments to rebate and discount estimates.
Free cash flow: strong, but capital intensive
A simple free-cash-flow calculation subtracts purchases of property and equipment from operating cash flow. In 2025, operating cash flow was $16.81 billion and capital expenditure was $7.84 billion, producing approximately $8.97 billion of simple FCF. That was below net income because working-capital needs expanded rapidly and Lilly was building inventory and capacity for growth.
For the first half of 2026, operating cash flow reached $16.02 billion and capital expenditure was $5.26 billion, implying about $10.76 billion of simple FCF. The improvement is impressive, but six-month cash flow can be distorted by payment timing and working-capital movements. Lilly also paid $13.3 billion for business-development activity in the period. Acquisition spending is excluded from the simple FCF calculation, even though it is a real use of shareholder capital.
Patent protection, competition, and regulation
Lilly’s 2025 Form 10-K lists estimated tirzepatide compound-patent expiration in 2036 in the U.S., 2037 in major European countries, and 2040 in Japan. These dates suggest a long commercial runway, but patents can be challenged, invalidated, designed around, or affected by litigation and regulatory exclusivity. Protection also does not prevent branded competition before expiration.
Novo Nordisk is the most visible competitor in incretins, while many large pharmaceutical and biotechnology companies are developing injectable and oral obesity therapies. Competition can pressure market share, pricing, formulary access, and the pace of innovation. Safety findings, tolerability, discontinuation rates, counterfeit or illegally compounded products, and product-liability litigation can also affect confidence and demand.
Government policy is another major variable. Wider Medicare and Medicaid access can expand treated populations, but public purchasing power can reduce net prices. Regulators determine approvals, labels, manufacturing compliance, and post-marketing requirements. Lilly’s value depends on a delicate combination of clinical evidence, safe production, reimbursement, patient access, and acceptable economics.
Valuation: what must go right?
At a reference price of $1,123 on September 10, 2026, Lilly’s equity value was approximately $1.0 trillion. The stock traded around 37.7 times trailing earnings and roughly 31 times the midpoint of 2026 non-GAAP EPS guidance. Using 2025 simple FCF, the free-cash-flow yield was below 1%; using annualized first-half 2026 simple FCF produces a materially higher but still demanding yield. Neither approach should be used alone because capacity spending is unusually high and working capital is volatile.
The valuation can work if Lilly sustains high double-digit revenue growth, converts capacity into product volume, defends strong margins, broadens access without excessive price erosion, and successfully launches Foundayo, retatrutide, and non-cardiometabolic assets. The downside is asymmetric if growth merely becomes normal: a lower earnings multiple can offset years of profit growth even when the underlying company remains excellent.
Bull case, bear case, and investor checklist
- Bull case: obesity treatment expands globally, oral therapy unlocks new demand, retatrutide broadens indications, manufacturing scale raises supply and margins, and other therapeutic areas diversify earnings.
- Bear case: realized prices fall faster than volume grows, competitors narrow the efficacy gap, safety or regulatory issues slow adoption, factory execution disappoints, or pipeline assets fail.
- Watch each quarter: Mounjaro and Zepbound volume and price, gross and performance margins, operating cash flow, capital expenditure, capacity milestones, payer access, pipeline readouts, and revenue concentration.
For a repeatable company-analysis process, see our stock-analysis framework. You can also compare other businesses in the Research hub.
Bottom line
Eli Lilly combines rare commercial momentum, high margins, improving cash generation, long-lived tirzepatide patent protection, and a pipeline capable of expanding an already enormous market. Management is also funding the manufacturing infrastructure needed to turn demand into delivered medicine.
The central investment risk is not that Lilly lacks a strong business. It is that the market already expects extraordinary results. Prospective shareholders need confidence in sustained volume growth, manageable price pressure, reliable manufacturing, successful pipeline execution, and years of high returns on today’s capital spending. Lilly may earn its premium, but the premium leaves little room for ordinary pharmaceutical setbacks.
Frequently asked questions
How dependent is Eli Lilly on Mounjaro and Zepbound?
The two tirzepatide brands generated $36.51 billion in 2025 and represented 56% of company revenue. They are Lilly’s primary growth engine and its largest concentration risk.
What is Eli Lilly’s free cash flow?
Using operating cash flow minus property-and-equipment purchases, simple FCF was about $8.97 billion in 2025 and $10.76 billion in the first half of 2026. This measure excludes acquisitions and can fluctuate with working capital.
When does Lilly’s tirzepatide patent expire?
Lilly’s 2025 Form 10-K lists estimated compound-patent expiration in 2036 in the U.S., 2037 in major European countries, and 2040 in Japan. Actual exclusivity can be affected by challenges, litigation, regulation, and other patents.
Primary sources
- Eli Lilly 2025 Form 10-K
- Lilly Second-Quarter 2026 Results
- Eli Lilly Second-Quarter 2026 Form 10-Q
- Lilly Q2 2026 Earnings Presentation
- Lilly’s Additional $4.5 Billion Indiana Manufacturing Commitment
Disclaimer: This article is for educational and informational purposes only. It is not investment, medical, tax, or legal advice, and it is not a recommendation concerning any medicine or treatment. Product indications, approvals, safety information, financial data, and market prices can change. Consult qualified healthcare professionals for medical decisions and review current regulatory labeling and company filings before acting.